Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
Rhea-AI Summary
Zevra Therapeutics (NasdaqGS: ZVRA) will present at the H.C. Wainwright BioConnect Investor Conference in New York on May 19, 2026, at 9:00 a.m. ET.
Executive leadership will present and hold one-on-one meetings, with a live webcast available via the Investor Relations section of Zevra’s website.
Positive
- None.
Negative
- None.
News Market Reaction – ZVRA
In the May 12 session, ZVRA gained 2.31%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Positive | -2.2% | Reported strong Q1 2026 revenue growth and cash from SDX portfolio sale. |
| Apr 22 | Earnings call details | Neutral | +1.9% | Announced timing and access details for Q1 2026 earnings call. |
| Mar 20 | CFO inducement grant | Neutral | +2.1% | Granted 300,000-share stock option package to new CFO under inducement plan. |
| Mar 16 | Asset sale and deleveraging | Positive | +1.6% | Sold SDX portfolio for $50 million and fully repaid $63 million term loan. |
| Mar 10 | Genetic testing partnership | Positive | +21.3% | Launched sponsored genetic testing program for suspected NPC patients with GeneDx. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive operationally, with share-price reactions mostly aligning, except for a negative move on strong Q1 2026 earnings.
Over the last six months, Zevra reported strong Q1 2026 results and a major SDX portfolio sale that left the balance sheet debt-free, alongside strategic collaborations and leadership changes. Most announcements, such as the $50 million SDX sale and the NPC genetic testing program, were followed by positive price reactions. The latest conference-participation news fits a pattern of ongoing investor outreach, following earlier earnings calls and updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference in New York, NY on Tuesday, May 19, 2026, at 9:00 a.m. ET.
Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026 and Zevra’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 6, 2026, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
